Compare · NVO vs ONC
NVO vs ONC
Side-by-side comparison of Novo Nordisk A/S (NVO) and BeOne Medicines Ltd. (ONC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and ONC operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $211.73B, about 6.9x ONC ($30.70B).
- Over the past year, NVO is down 33.0% and ONC is up 3.6% - ONC leads by 36.6 points.
- ONC has been more active in the news (35 items in the past 4 weeks vs 3 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 6 for ONC).
- Company
- Novo Nordisk A/S
- BeOne Medicines Ltd.
- Price
- $47.40+3.29%
- $276.19+1.53%
- Market cap
- $211.73B
- $30.70B
- 1M return
- +6.83%
- -10.77%
- 1Y return
- -32.98%
- +3.59%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 3
- 35
- Recent ratings
- 25
- 6
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest ONC
- SEC Form 144 filed by BeOne Medicines Ltd.
- President and COO Wu Xiaobin sold $361,997 worth of American Depositary Shares (1,357 units at $266.76), closing all direct ownership in the company (SEC Form 4) to cover taxes
- SVP, General Counsel Lee Chan Henry sold $156,925 worth of American Depositary Shares (590 units at $265.98), closing all direct ownership in the company (SEC Form 4) to cover taxes
- Chief Executive Officer Oyler John sold $980,686 worth of American Depositary Shares (3,693 units at $265.55), closing all direct ownership in the company (SEC Form 4) to satisfy tax liability
- President, Global Head of R&D Wang Lai sold $310,236 worth of American Depositary Shares (1,169 units at $265.39), closing all direct ownership in the company (SEC Form 4) (tax liability)
- SEC Form 144 filed by BeOne Medicines Ltd.
- Principal Accounting Officer Ball Titus B. was granted 31,213 units of Ordinary Shares and sold $43,467 worth of American Depositary Shares (169 units at $257.20), closing all direct ownership in the company (SEC Form 4) (for tax liability)
- President, Global Head of R&D Wang Lai was granted 118,625 units of Ordinary Shares and sold $197,318 worth of American Depositary Shares (756 units at $261.00), closing all direct ownership in the company (SEC Form 4) (tax liability)
- Chief Financial Officer Rosenberg Aaron was granted 71,175 units of Ordinary Shares and sold $162,637 worth of American Depositary Shares (631 units at $257.74), closing all direct ownership in the company (SEC Form 4) (for withholding tax)
- SVP, General Counsel Lee Chan Henry was granted 45,071 units of Ordinary Shares and sold $110,268 worth of American Depositary Shares (428 units at $257.63), closing all direct ownership in the company (SEC Form 4) (tax withholding)